MA26774A1 - Derives de pyridinyl et de phenyl - Google Patents

Derives de pyridinyl et de phenyl

Info

Publication number
MA26774A1
MA26774A1 MA26302A MA26302A MA26774A1 MA 26774 A1 MA26774 A1 MA 26774A1 MA 26302 A MA26302 A MA 26302A MA 26302 A MA26302 A MA 26302A MA 26774 A1 MA26774 A1 MA 26774A1
Authority
MA
Morocco
Prior art keywords
pyridinyl
phenyl derivatives
phenyl
derivatives
Prior art date
Application number
MA26302A
Other languages
English (en)
Inventor
Guido Galley
Thierry Godel
Walter Hunkeler
Patrick Schnider
Michael Boes
Torsten Hoffmann
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26774A1 publication Critical patent/MA26774A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/29—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C07C233/33—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/44—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
MA26302A 1999-02-24 2001-08-23 Derives de pyridinyl et de phenyl MA26774A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99103502 1999-02-24

Publications (1)

Publication Number Publication Date
MA26774A1 true MA26774A1 (fr) 2004-12-20

Family

ID=8237623

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26302A MA26774A1 (fr) 1999-02-24 2001-08-23 Derives de pyridinyl et de phenyl

Country Status (30)

Country Link
US (2) US6407111B1 (fr)
EP (1) EP1157006B1 (fr)
JP (1) JP4070957B2 (fr)
KR (1) KR100514236B1 (fr)
CN (1) CN1131212C (fr)
AR (1) AR044719A1 (fr)
AT (1) ATE343565T1 (fr)
AU (1) AU767123B2 (fr)
BR (1) BR0008489A (fr)
CA (1) CA2364665C (fr)
CO (1) CO5140088A1 (fr)
CZ (1) CZ20013046A3 (fr)
DE (1) DE60031513T2 (fr)
ES (1) ES2272264T3 (fr)
HK (1) HK1044941B (fr)
HR (1) HRP20010603A2 (fr)
HU (1) HUP0200124A3 (fr)
IL (1) IL144717A0 (fr)
JO (1) JO2244B1 (fr)
MA (1) MA26774A1 (fr)
MY (1) MY133237A (fr)
NO (1) NO320321B1 (fr)
NZ (1) NZ513322A (fr)
PE (1) PE20010009A1 (fr)
PL (1) PL350427A1 (fr)
RU (1) RU2238264C2 (fr)
TR (1) TR200102490T2 (fr)
WO (1) WO2000050398A2 (fr)
YU (1) YU59801A (fr)
ZA (1) ZA200106258B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1394150T3 (da) * 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
KR100501608B1 (ko) * 2000-07-14 2005-07-18 에프. 호프만-라 로슈 아게 4-페닐-피리딘 유도체의 ｎｋ1 수용체의 길항성선구약물로서의 ｎ-산화물
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US6531597B2 (en) * 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7176322B2 (en) * 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
WO2004014871A1 (fr) * 2002-08-08 2004-02-19 Amgen Inc. Ligands de recepteur vanilloide et leur utilisation dans des traitements
BR0314126A (pt) 2002-09-20 2005-06-28 Pfizer Prod Inc Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio
EP1643998B1 (fr) 2003-07-03 2007-08-29 F. Hoffmann-La Roche Ag Antagonistes doubles des recepteurs nk1/nk3 pour traiter la schizophrenie
TWI280239B (en) 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
MY139645A (en) * 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
US7534798B2 (en) * 2004-02-11 2009-05-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
KR101238525B1 (ko) 2004-12-31 2013-02-28 레디 유에스 테라퓨틱스 인코포레이티드 Ｃｅｔｐ 저해제로서의 신규 벤질아민 유도체
WO2006089311A1 (fr) * 2005-02-15 2006-08-24 Amgen Inc. Ligands des recepteurs vanilloides et leurs utilisations therapeutiques
UA90708C2 (ru) 2005-02-25 2010-05-25 Ф. Хоффманн-Ля Рош Аг Таблетки с улучшенной дисперсностью лекарственного вещества
EP1877400A1 (fr) * 2005-04-15 2008-01-16 Amgen, Inc Ligands recepteurs de vanilloide et leur utilisation dans les traitements
DK1928427T3 (da) 2005-09-23 2010-03-08 Hoffmann La Roche Hidtil ukendt dosisformulering
HUE032640T2 (en) 2005-11-08 2017-10-30 Vertex Pharma Heterocyclic modulator of ATP-binding cassette transcripts
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
GB0603190D0 (en) * 2006-02-16 2006-03-29 Enigma Diagnostics Ltd Detection system
KR100932093B1 (ko) * 2006-09-27 2009-12-16 주식회사종근당 미세소관 형성 저해제로서 유용한 벤조페논 유도체
WO2008057282A1 (fr) * 2006-10-26 2008-05-15 Amgen Inc. Agents modulant le récepteur sensible au calcium
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2212284B1 (fr) * 2007-10-15 2014-04-30 Amgen Inc. Agents de modulation du récepteur du calcium
KR20100101130A (ko) 2007-12-07 2010-09-16 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
CA2707494C (fr) 2007-12-07 2018-04-24 Vertex Pharmaceuticals Incorporated Procedes de fabrication d'acides cycloalkylcarboxamido-pyridine benzoiques
NZ602030A (en) 2008-02-28 2014-02-28 Vertex Pharma Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
WO2010042642A1 (fr) * 2008-10-08 2010-04-15 Amgen Inc. Agents modulateurs des récepteurs de calcium
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
US8470820B2 (en) * 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
LT3150198T (lt) 2010-04-07 2021-12-10 Vertex Pharmaceuticals Incorporated 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
CA2850022C (fr) 2011-09-27 2018-05-01 Dr. Reddy's Laboratories, Ltd. Derives de 5 - benzylaminomethyl - 6 - aminopyrazolo [3,4-b] pyridine utiles comme inhibiteurs de la cholesteryl ester-transfer proteine (cetp) dans le traitement de l'atherosc lerose
PT3068392T (pt) 2013-11-12 2021-05-14 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr)
HUE055423T2 (hu) 2014-11-18 2021-11-29 Vertex Pharma Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
CN109678815B (zh) * 2019-01-09 2022-11-29 中国药科大学 N-苄基苯甲酰胺类衍生物及其制备方法与制药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3112356A (en) * 1961-04-28 1963-11-26 Du Pont Benzoic acid ester dielectric compositions and electrical apparatus in combination therewith
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
SK283070B6 (sk) 1993-12-29 2003-02-04 Merck Sharp & Dohme Limited Substituované morfolínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
AU2139097A (en) * 1996-03-01 1997-09-16 Eli Lilly And Company Methods of treating or preventing sleep apnea
DE69836378T2 (de) * 1997-07-01 2007-10-11 Warner-Lambert Co. Llc Benzoesäure- und Benzamid-Derivate von Anthranilsäure und ihre Anwendung als MEK-Inhibitoren
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
CA2358438A1 (fr) * 1999-01-07 2000-07-13 David Thomas Dudley Methode antivirale utilisant des inhibiteurs de mek
DK1394150T3 (da) * 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
DK1103545T3 (da) * 1999-11-29 2004-03-15 Hoffmann La Roche 2-(3,5-bis-trifluormethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide

Also Published As

Publication number Publication date
ES2272264T3 (es) 2007-05-01
NO20014096D0 (no) 2001-08-23
HRP20010603A2 (en) 2002-08-31
JP2002537379A (ja) 2002-11-05
PL350427A1 (en) 2002-12-16
TR200102490T2 (tr) 2001-12-21
NZ513322A (en) 2004-07-30
DE60031513D1 (de) 2006-12-07
PE20010009A1 (es) 2001-02-07
ZA200106258B (en) 2002-10-30
MY133237A (en) 2007-10-31
JO2244B1 (en) 2004-10-07
BR0008489A (pt) 2002-02-05
HK1044941A1 (en) 2002-11-08
NO20014096L (no) 2001-08-23
WO2000050398A2 (fr) 2000-08-31
DE60031513T2 (de) 2007-08-30
US6596773B2 (en) 2003-07-22
IL144717A0 (en) 2002-06-30
NO320321B1 (no) 2005-11-21
CZ20013046A3 (cs) 2002-02-13
CA2364665A1 (fr) 2000-08-31
US20020111367A1 (en) 2002-08-15
AU3422500A (en) 2000-09-14
AU767123B2 (en) 2003-10-30
HUP0200124A2 (en) 2002-08-28
US6407111B1 (en) 2002-06-18
HK1044941B (zh) 2004-05-07
KR100514236B1 (ko) 2005-09-13
AR044719A1 (es) 2005-10-05
CN1131212C (zh) 2003-12-17
CO5140088A1 (es) 2002-03-22
ATE343565T1 (de) 2006-11-15
KR20010102346A (ko) 2001-11-15
EP1157006B1 (fr) 2006-10-25
WO2000050398A3 (fr) 2001-04-05
JP4070957B2 (ja) 2008-04-02
RU2238264C2 (ru) 2004-10-20
CN1341101A (zh) 2002-03-20
HUP0200124A3 (en) 2004-03-01
YU59801A (sh) 2005-07-19
EP1157006A2 (fr) 2001-11-28
CA2364665C (fr) 2009-09-15

Similar Documents

Publication Publication Date Title
MA26774A1 (fr) Derives de pyridinyl et de phenyl
NO20000885L (no) 4-Fenyl-pyridin-derivater
NO20021077L (no) Amino-triazolopyridin-derivater
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
ATE263748T1 (de) Admantan-derivate
ATE293104T1 (de) Thiazolylamid-derivate
IS6128A (is) 13-Metýl-erýþrómýsín afleiður
DK1187814T3 (da) 5-phenyl-pyrimidinderivater
DE60021170D1 (de) Verstärker
NO20021803D0 (no) Isoksazolkarboksamid-derivater
ATE257148T1 (de) Propargyletherderivate
ATE273272T1 (de) Mevinolinderivate
ATE374747T1 (de) Monofluoralkylderivate
DK1187815T3 (da) 4-phenyl-pyrimidinderivater
DK1218340T3 (da) 4-hydroxybiphenylhydrazid-derivater
ATE293592T1 (de) Resorcinderivate
DE60032898D1 (de) Arylthiazolidindion- und aryloxazolidinderivate
NO20020212L (no) 3-amino-2-benzyl-1-fenyl-propanderivater
NO20022867D0 (no) Syklopentenon-derivater
TR200002831A3 (tr) Kinolin-4-Il türevleri I
DE60117096D1 (de) Dihydroindol- und tetrahydrochinolinderivate
DK1189886T3 (da) Ethansulfonyl-piperidinderivater
DE60001736D1 (de) 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
DE60045575D1 (de) Verstärker
DE59909774D1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate